Details for Patent: 7,387,793

Which drugs does patent 7,387,793 protect, and when does it expire?

Patent 7,387,793 protects AMRIX and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 7,387,793

Title:	Modified release dosage forms of skeletal muscle relaxants
Abstract:	A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration--time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.
Inventor(s):	Venkatesh; Gopi (Vandalia, OH), Clevenger; James M. (Vandalia, OH)
Assignee:	Eurand, Inc. (Vandalia, OH)
Application Number:	10/713,929
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,387,793
Patent Claim Types: see list of patent claims	Formulation; Compound; Dosage form;

Drugs Protected by US Patent 7,387,793

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777-001	Feb 1, 2007	AB	RX	Yes	No			Y
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777-002	Feb 1, 2007	AB	RX	Yes	Yes			Y

International Family Members for US Patent 7,387,793

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
World Intellectual Property Organization (WIPO)	2005048996